Trans-cyclooctene Bioorthogonal Delivery for Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy methods, such as those involving TLR agonists and STING agonists, face challenges in targeted and efficient delivery of payloads to tumor sites, limiting their effectiveness in activating immune responses and inhibiting tumor growth.
Innovation Solution
Development of trans-cyclooctene derivatives that utilize bioorthogonal chemistry for selective delivery of TLR agonists and STING agonists to tumor sites through bioorthogonal conjugation with tetrazine-functionalized alginate, enabling precise and localized immune activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer immunotherapy methods using TLR agonists and STING agonists are used, then immune response activation is achieved, but targeted delivery to tumor sites is limited reducing effectiveness
Solution Approach 1:
The patent employs trans-cyclooctene (TCO) as a bioorthogonal intermediary that selectively binds to tetrazine-functionalized alginate at tumor sites. This intermediary enables precise targeted delivery of TLR agonists and STING agonists without interfering with biological systems, resolving the contradiction between achieving reliable immune activation and precise targeted delivery by mediating between the therapeutic agents and tumor site through selective bioorthogonal chemistry
Solution Approach 2:
The patent implements local quality by functionalizing alginate with tetrazine groups specifically at the tumor site, creating a localized region with unique binding properties. The TCO-conjugated therapeutic agents then selectively bind to this locally modified alginate structure, ensuring that immune response activation occurs precisely where needed rather than systemically, thereby improving both targeted delivery precision and treatment effectiveness
2Adaptability or versatility
If systemic administration of immunomodulatory agents is used, then broad immune activation occurs, but off-target effects and reduced efficacy at tumor site result
Solution Approach 1:
The patent segments the immune activation process into two distinct components: (1) TCO-conjugated TLR agonists and STING agonists that can systemically activate immune pathways, and (2) tetrazine-functionalized alginate that localizes the therapeutic effect at the tumor site through selective binding. This segmentation allows broad immune activation capability while ensuring concentrated efficacy at the tumor site by separating the immune activation function from the localization function
Solution Approach 2:
The TCO-tetrazine bioorthogonal pair serves as a mediator that connects systemically administered TCO-conjugated immunomodulatory agents with tumor-site-localized tetrazine-functionalized alginate. This intermediary mechanism enables the agents to maintain their broad immune activation capability while being selectively retained at the tumor site, resolving the contradiction between versatility and targeted efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the immune response against tumors by ensuring targeted delivery of immunomodulatory agents, thereby inhibiting tumor growth and metastasis, and improving the efficacy of cancer immunotherapy.
Implementation Method 1
trans-cyclooctene derivatives that utilize bioorthogonal chemistry for selective delivery of TLR agonists and STING agonists to tumor sites through bioorthogonal conjugation with tetrazine-functionalized alginate
Data Source
AI summary
Trans-cyclooctene conjugates of therapeutic agents may be used for bioorthogonal delivery to a targeted location in a subject. The compositions and methods have applications in the treatment of various diseases or conditions including cancer, tumor growths, and bacterial infections.